June 2019 - Volume 3 - Issue S1 - Contributor Index

Author:
Waage, A.

PS1374 PROGNOSIS IN ELDERLY MULTIPLE MYELOMA PATIENTS IN THE HOVON-87/NMSG-18 STUDY BASED ON REVISED ISS AND SKY92-ISS

Kuiper, R.; Broijl, A.; Vliet, M.H. van; More

HemaSphere. 3(S1):628-629, June 2019.

S1602 CARFILZOMIB AND DEXAMETHASONE MAINTENANCE PROLONG TIME TO PROGRESSION: FOLLOWING SALVAGE ASCT IN MULTIPLE MYELOMA: A RANDOMIZED PHASE 2 TRIAL BY THE NORDIC MYELOMA STUDY GROUP

Gregersen, H.; Peceliunas, V.; Remes, K.; More

HemaSphere. 3(S1):737-738, June 2019.

Author:
Wach, M.
Author:
Wada, C.
Author:
Wada, H.

PS1277 EVALUATION OF THE IMMUNITY TO MEASLES, MUMPS AND RUBELLA IN ADULT PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

Kawamura, K.; Nakasone, H.; Wada, H.; More

HemaSphere. 3(S1):584-585, June 2019.

S1639 SAFETY AND EFFICACY OF LIVE ATTENUATED VARICELLA VACCINE FOR PREVENTING VARICELLA ZOSTER VIRUS DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A PROSPECTIVE SINGLE-CENTER STUDY

Kawamura, K.; Nakasone, H.; Akahoshi, Y.; More

HemaSphere. 3(S1):758, June 2019.

Author:
Wadleigh, M.

S828 A RANDOMIZED, DOUBLE BLIND PHASE 2 STUDY OF 3 DIFFERENT DOSES OF PRM-151 IN PATIENTS WITH MYELOFIBROSIS WHO WERE PREVIOUSLY TREATED WITH OR INELIGIBLE FOR RUXOLITINIB

Verstovsek, S.; Talpaz, M.; Wadleigh, M.; More

HemaSphere. 3(S1):367, June 2019.

Author:
Wagenführ, L.

S1614 CHROMOSOMAL ABNORMALITIES DETERMINE OUTCOME IN NPM1MUT/FLT3-ITDNEG/LOW ACUTE MYELOID LEUKEMIA

Angenendt, L.; Röllig, C.; Montesinos, P.; More

HemaSphere. 3(S1):744-745, June 2019.

Author:
Wagner, C.

PS1327 PRO-NECROPTOTIC RIPK3 AS A STAGE-DEPENDENT MARKER IN THE BONE MARROW OF PATIENTS WITH MDS AND CMML

Dill, V.; Jilg, S.; Wagner, C.; More

HemaSphere. 3(S1):605-606, June 2019.

Author:
Wagner, F.
Author:
Wagner, K.

PS971 AT1413 ANTIBODY DERIVED FROM A CURED AML PATIENT RECOGNIZES A UNIQUE CD43 EPITOPE SHARED BY AML, MDS AND MELANOMA AND HAS IN VIVO ACTIVITY AS UNMODIFIED ANTIBODY AND AS BISPECIFIC T CELL ENGAGER

De Jong, G.; Bartels, L.; Kedde, M.; More

HemaSphere. 3(S1):437-438, June 2019.

Author:
Wagner, L.

PS1384 TREATMENT CHOICES AND OUTCOMES FOR PATIENTS WITH MULTIPLE MYELOMA AFTER RELAPSE ON LENALIDOMIDE MAINTENANCE THERAPY: RESULTS FROM THE CONNECT® MM REGISTRY

Jagannath, S.; Narang, M.; Ailawadhi, S.; More

HemaSphere. 3(S1):634, June 2019.

PS1073 PRELIMINARY RESULTS OF ASTX660, A NOVEL NON-PEPTIDOMIMETIC CIAP1/2 AND XIAP ANTAGONIST, IN RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA AND CUTANEOUS T CELL LYMPHOMA

Mehta, A.; Hollebecque, A.; Foss, F.; More

HemaSphere. 3(S1):486, June 2019.

PS1075 ANTITUMOR ACTIVITY OF PEMBROLIZUMAB PLUS DINACICLIB IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA: THE PHASE 1B KEYNOTE-155 STUDY

Gregory, G.; Walker, P.; Mahadevan, D.; More

HemaSphere. 3(S1):487, June 2019.

Author:
Wahida, A.

PS1327 PRO-NECROPTOTIC RIPK3 AS A STAGE-DEPENDENT MARKER IN THE BONE MARROW OF PATIENTS WITH MDS AND CMML

Dill, V.; Jilg, S.; Wagner, C.; More

HemaSphere. 3(S1):605-606, June 2019.

Author:
Wahlin, B.

PF311 ISOLATED PRIMARY ADRENAL LYMPHOMA (IPAL) - AN EMERGING LYMPHOMA ENTITY? RESULTS OF A RETROSPECTIVE MULTICENTER STUDY

Majidi, F.; Martino, S.; Kondakci, M.; More

HemaSphere. 3(S1):108, June 2019.

Author:
Wais, V.

PS1542 RESPIRATORY SYNCYTIAL VIRUS AND HUMAN METAPNEUMOVIRUS INFECTIONS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: IMPACT OF THE IMMUNODEFICIENCY SCORING INDEX AND RIBAVIRIN TREATMENT ON THE OUTCOMES

Akhmedov, M.; Wais, V.; Sala, E.; More

HemaSphere. 3(S1):712, June 2019.

Author:
Wajant, H.

PS1001 HACE1, A NOVEL TUMOR SUPPRESSOR GENE WHICH REGULATE THE RESPONSE OF VENETOCLAX, GANT61 AND NECROPTOSIS ACTIVATORS BY CONTROLLING C-FLIP, GLI2 AND BCL2 GENES IN ACUTE MYELOID LEUKEMIA

Garitano, A.; Teufel, E.; Kreckel, J.; More

HemaSphere. 3(S1):450, June 2019.

Author:
Wakabayashi, M.

PS1259 LONG-TERM FOLLOW-UP OF JCOG0406 STUDY: INTENSIVE IMMUNOCHEMOTHERAPY (R-HIGH CHOP/CHASER) FOLLOWED BY HIGH-DOSE CHEMOTHERAPY (LEED) WITH AUTO-PBSCT IN UNTREATED MANTLE CELL LYMPHOMA

Ogura, M.; Yamamoto, K.; Morishima, Y.; More

HemaSphere. 3(S1):575-576, June 2019.

Author:
Wakeman, S.

PF175 MULTICENTRE STANDARDIZATION OF MINIMAL RESIDUAL DISEASE DETECTION AND QUANTITATION USING THE EUROCLONALITY-NGS ASSAY

Svaton, M.; Fronkova, E.; Kotrova, M.; More

HemaSphere. 3(S1):39-40, June 2019.

Author:
Wakita, K.
Author:
Walewski, J.

S820 FRONTLINE BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY FOR STAGE 3/4 CLASSICAL HODGKIN LYMPHOMA: 3-YEAR UPDATE OF THE ECHELON-1 STUDY

Gallamini, A.; Straus, D.; Dlugosz-Danecka, M.; More

HemaSphere. 3(S1):362-363, June 2019.

Author:
Wali, Y.
Author:
Walker, B.

PS1386 CARFILZOMIB AS PART OF A DOSE DENSE, LESS DOSE INTENSE TOTAL THERAPY APPROACH FOR HIGH RISK MYELOMA

Van Rhee, F.; Wang, H.; Thanendrarajan, S.; More

HemaSphere. 3(S1):635, June 2019.

Author:
Walker, J.S.
Author:
Walker, P.

PS1075 ANTITUMOR ACTIVITY OF PEMBROLIZUMAB PLUS DINACICLIB IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA: THE PHASE 1B KEYNOTE-155 STUDY

Gregory, G.; Walker, P.; Mahadevan, D.; More

HemaSphere. 3(S1):487, June 2019.

Author:
Wall, D.
Author:
Wall, M.

S1614 CHROMOSOMAL ABNORMALITIES DETERMINE OUTCOME IN NPM1MUT/FLT3-ITDNEG/LOW ACUTE MYELOID LEUKEMIA

Angenendt, L.; Röllig, C.; Montesinos, P.; More

HemaSphere. 3(S1):744-745, June 2019.

Author:
Wallace, P.
Author:
Waller, C.

S1608 RUXOLITINIB PLUS POMALIDOMIDE IN MYELOFIBROSIS WITH ANEMIA: RESULTS FROM THE MPNSG-0212 COMBINATION TRIAL (NCT01644110)

Stegelmann, F.; Koschmieder, S.; Isfort, S.; More

HemaSphere. 3(S1):740-741, June 2019.

Author:
Waller, J.

PB2300 IMPACT OF SICKLE CELL DISEASE FROM PATIENTS’ AND PHYSICIANS’ PERSPECTIVES: RESULTS FROM THE INTERNATIONAL SICKLE CELL WORLD ASSESSMENT SURVEY (SWAY)

Osunkwo, I.; Abboud, M.; Andemariam, B.; More

HemaSphere. 3(S1):1026-1027, June 2019.

PF761 REDUCED INTENSITY CONDITIONING REGIMEN WITH ALEMTUZUMAB BASED T CELL DEPLETION ENABLES EARLY POST-TRANSPLANTATION CELLULAR INTERVENTION RESTORING GRAFT VERSUS LEUKEMIA EFFECTS IN OLDER AML PATIENTS

Koster, E.; von dem Borne, P.; Bogers, L.; More

HemaSphere. 3(S1):334-335, June 2019.

Author:
Walter, C.
Author:
Walter, R.
Author:
Walter, R.B.

PF253 SAFETY AND RESOURCE UTILIZATION FOLLOWING EARLY HOSPITAL DISCHARGE AFTER INDUCTION CHEMOTHERAPY FOR ACUTE MYELOID LEUKEMIA (AML): A 4-YEAR RETROSPECTIVE ANALYSIS

Howard, N.P.; Halpern, A.B.; Othus, M.; More

HemaSphere. 3(S1):78, June 2019.

Author:
Walter, W.
Author:
Walters, M.
Author:
Walters, M.C.

S141 CLINICAL OUTCOMES OF LENTIGLOBIN GENE THERAPY FOR TRANSFUSION-DEPENDENT β-THALASSAEMIA (TDT) FOLLOWING COMPLETION OF THE NORTHSTAR (HGB-204) STUDY

Walters, M.C.; Kwiatkowski, J.L.; Rasko, J.E.J.; More

HemaSphere. 3(S1):22, June 2019.

S1632 SAFETY AND EFFICACY OF LENTIGLOBIN GENE THERAPY IN PATIENTS WITH TRANSFUSION-DEPENDENT B-THALASSAEMIA AND NON-B0/B0 GENOTYPES IN THE PHASE 3 NORTHSTAR-2 STUDY

Locatelli, F.; Thompson, A.A.; Hongeng, S.; More

HemaSphere. 3(S1):754, June 2019.

S1633 UPDATED RESULTS FROM THE HGB-206 STUDY IN PATIENTS WITH SEVERE SICKLE CELL DISEASE TREATED UNDER A REVISED PROTOCOL WITH LENTIGLOBIN GENE THERAPY USING PLERIXAFOR-MOBILISED HAEMATOPOIETIC STEM CELLS

Kanter, J.; Thompson, A.A.; Mapara, M.Y.; More

HemaSphere. 3(S1):754-755, June 2019.

Author:
Walzer, T.

PS1303 CHRONIC TCR STIMULATION PROMOTES PERIPHERAL T-CELL LYMPHOMAGENESIS AND INDUCES ADDICTION TO SYK AND NK RECEPTOR SIGNALING

Carras, S.; Chartoire, D.; Marcais, A.; More

HemaSphere. 3(S1):595, June 2019.

Author:
Wan, Y.

S837 TREATMENT WITH IMETELSTAT PROVIDES DURABLE TRANSFUSION INDEPENDENCE (TI) IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER RISK MDS (LR-MDS) RELAPSED/REFRACTORY (R/R) TO ERYTHROPOIESIS STIMULATING AGENTS (ESAS)

Fenaux, P.; Steensma, D.P.; Van Eygen, K.; More

HemaSphere. 3(S1):372-373, June 2019.

Author:
Wandroo, F.

PS1182 REAL WORLD TYROSINE KINASE INHIBITOR TREATMENT PATHWAYS, MONITORING PATTERNS AND RESPONSES COMPARED WITH ELN RECOMMENDATIONS IN CHRONIC MYELOID LEUKAEMIA: FINAL ANALYSIS OF THE UK TARGET CML STUDY

Milojkovic, D.; Cross, N.C.; Ali, S.; More

HemaSphere. 3(S1):538-539, June 2019.

Author:
Wang, A.

PS1159 POOLED ANALYSIS OF SAFETY DATA FROM MONOTHERAPY STUDIES OF THE BRUTON TYROSINE KINASE (BTK) INHIBITOR, ZANUBRUTINIB (BGB-3111), IN B-CELL MALIGNANCIES

Tam, C.S.; Opat, S.; Zhu, J.; More

HemaSphere. 3(S1):526, June 2019.

Author:
Wang, A.K.

PS1221 LONG-TERM EFFICACY AND SAFETY OF INOTERSEN FOR HEREDITARY TRANSTHYRETIN AMYLOIDOSIS: NEURO-TTR OPEN-LABEL EXTENSION 2-YEAR UPDATE

Brannagan, T.; Cruz, M. Waddington; Wang, A.K.; More

HemaSphere. 3(S1):557, June 2019.

Author:
Wang, C.

PS1094 MANAGING CYTOKINE RELEASE SYNDROME (CRS) AND NEUROTOXICITY WITH STEP-FRACTIONATED DOSING OF MOSUNETUZUMAB IN RELAPSED/REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (NHL)

Yoon, S.-S.; Matasar, M.; Sehn, L.H.; More

HemaSphere. 3(S1):496, June 2019.

Author:
Wang, C.-C.

PF805 INCIDENCE, CLINICAL FEATURES, RISK FACTORS AND OUTCOMES OF REFRACTORY ACQUIRED IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA: A CHINESE MULTI-CENTER EXPERIENCE

Gui, R.-Y.; Zhang, G.-C.; Wang, C.-C.; More

HemaSphere. 3(S1):355, June 2019.

Author:
Wang, D.

PS1075 ANTITUMOR ACTIVITY OF PEMBROLIZUMAB PLUS DINACICLIB IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA: THE PHASE 1B KEYNOTE-155 STUDY

Gregory, G.; Walker, P.; Mahadevan, D.; More

HemaSphere. 3(S1):487, June 2019.

Author:
Wang, E.

PF668 RESULTS FROM ONGOING PHASE 1/2 CLINICAL TRIAL OF TAGRAXOFUSP (SL-401) IN PATIENTS WITH INTERMEDIATE, OR HIGH RISK, RELAPSED/REFRACTORY MYELOFIBROSIS

Pemmaraju, N.; Ali, H.; Gupta, V.; More

HemaSphere. 3(S1):286-287, June 2019.

PF672 RESULTS FROM ONGOING PHASE 1/2 CLINICAL TRIAL OF TAGRAXOFUSP (SL-401) IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)

Patnaik, M.; Ali, H.; Gupta, V.; More

HemaSphere. 3(S1):289, June 2019.

PS1063 RESULTS OF PIVOTAL PHASE 2 CLINICAL TRIAL OF TAGRAXOFUSP (SL-401) IN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)

Pemmaraju, N.; Lane, A.; Sweet, K.; More

HemaSphere. 3(S1):481, June 2019.

PS1065 OPEN-LABEL STUDY OF GILTERITINIB, GILTERITINIB PLUS AZACITIDINE, OR AZACITIDINE ALONE IN NEWLY DIAGNOSED FLT3-MUTATED AML PATIENTS INELIGIBLE FOR INTENSIVE CHEMOTHERAPY: RESULTS FROM THE SAFETY COHORT

Esteve, J.; Schots, R.; Del Castillo, T. Bernal; More

HemaSphere. 3(S1):482, June 2019.

Author:
Wang, E.S.

PF269 FT-2102, AN IDH1 M INHIBITOR, COMBINED WITH AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS): RESULTS FROM A PHASE 1 STUDY

Cortes, J.E.; Watts, J.; Baer, M.; More

HemaSphere. 3(S1):86-87, June 2019.

PF272 GLASDEGIB WITH LDAC IN NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) UNSUITABLE FOR INTENSIVE CHEMOTHERAPY: EFFECTS ON TRANSFUSIONS AND MARROW RECOVERY VS LDAC ALONE

Wang, E.S.; Heuser, M.; Montesinos, P.; More

HemaSphere. 3(S1):87, June 2019.

PS1212 UPDATED RESULTS FROM PHASE I TRIALS ASSESSING A NKG2D CAR T-CELL APPROACH IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME PATIENTS

Sallman, D.A.; Davila, M.; Brayer, J.B.; More

HemaSphere. 3(S1):552-553, June 2019.

Author:
Wang, F.

PF205 RNA BASED IMMUNE SIGNATURES MAY PREDICT RESPONSES TO PD-1 INHIBITION AND AZACITIDINE TREATMENT IN ACUTE MYELOID LEUKEMIA (AML): A SUBSET ANALYSIS OF A PHASE 2 STUDY

Abbas, H.; Alfayez, M.; Wang, F.; More

HemaSphere. 3(S1):54-55, June 2019.

S833 THE SINGLE-CELL ATLAS OF DRIVER MUTATIONS IN AML

Morita, K.; Wang, F.; Jahn, K.; More

HemaSphere. 3(S1):370, June 2019.